Keyphrases
Abiraterone Acetate
100%
Prednisone
100%
Androgens
100%
Serum PSA
100%
Dynamic PSA
100%
Abiraterone
83%
PSA Response
66%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
50%
Serum Androgens
50%
Androgen Levels
50%
PSA Decline
50%
Prostate Cancer Patients
33%
Testosterone
33%
Limit of Quantification
33%
Randomized Double-blind Placebo-controlled Study
16%
Placebo
16%
Prostate Cancer Progression
16%
Ligand-independent
16%
Ultrasensitive
16%
Two-dimensional Liquid Chromatography
16%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
16%
Serum Testosterone
16%
Confidence Interval
16%
Odds Ratio
16%
Logistic Regression
16%
Dehydroepiandrosterone Sulfate (DHEAS)
16%
Androstenedione
16%
Ultrasensitive Assay
16%
Postdocetaxel
16%
Low Dose Prednisone
16%
Neuroscience
Androgen
100%
Abiraterone Acetate
100%
Prednisone
70%
Abiraterone
50%
Prostate
30%
Placebo
20%
Docetaxel
10%
Androstenedione
10%
Dehydroepiandrosterone Sulfate
10%
Mass Spectrometry
10%
Agricultural and Biological Sciences
Androgen
100%
Abiraterone
100%
Prednisone
70%
Placebo
20%
Tandem Mass Spectrometry
10%
Confidence Interval
10%
Androstenedione
10%
Docetaxel
10%
Liquid Chromatography
10%
Odds Ratio
10%
Dehydroepiandrosterone Sulfate
10%